Clinical utility of chromogranin A and octreotide in large cell neuro endocrine carcinoma of the uterine corpus

Shohreh Shahabi, Ilenia Pellicciotta, June Hou, Sarah Graceffa, Gloria S. Huang, Robert N. Samuelson, Gary L. Goldberg

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Primary neuroendocrine tumors of the female genital tract have been described in the cervix, ovaries and uterus. Large cell neuroendocrine carcinoma (LCNC) of the uterine corpus is the least common and appears to behave the most aggressively. We report a rare case of a large cell neuroendocrine tumor of the endometrium. These tumors are not well characterized, unlike neuroendocrine tumors of the uterine cervix. Consequently, the optimal management remains still unclear. The treatment of our case consisted of surgery, radiotherapy, chemotherapy, and octreotide. Despite the aggressive treatment, the patient died of disease progression 12 months after the initial diagnosis. We discuss the diagnosis, prognosis, and treatment options for LCNC of the genital tract, and potential future therapeutics.

Original languageEnglish (US)
Pages (from-to)129-131
Number of pages3
JournalRare Tumors
Volume3
Issue number4
DOIs
StatePublished - 2011

Fingerprint

Chromogranin A
Octreotide
Endocrine Cells
Neuroendocrine Tumors
Carcinoma
Neuroendocrine Carcinoma
Large Cell Carcinoma
Cervix Uteri
Therapeutics
Endometrium
Disease Progression
Ovary
Radiotherapy
Drug Therapy
Neoplasms

Keywords

  • Chromogranin A
  • Large cell neuroendocrine carcinoma
  • Octerotide
  • Uterine corpus

ASJC Scopus subject areas

  • Oncology
  • Histology

Cite this

Shahabi, S., Pellicciotta, I., Hou, J., Graceffa, S., Huang, G. S., Samuelson, R. N., & Goldberg, G. L. (2011). Clinical utility of chromogranin A and octreotide in large cell neuro endocrine carcinoma of the uterine corpus. Rare Tumors, 3(4), 129-131. https://doi.org/10.4081/rt.2011.e41

Clinical utility of chromogranin A and octreotide in large cell neuro endocrine carcinoma of the uterine corpus. / Shahabi, Shohreh; Pellicciotta, Ilenia; Hou, June; Graceffa, Sarah; Huang, Gloria S.; Samuelson, Robert N.; Goldberg, Gary L.

In: Rare Tumors, Vol. 3, No. 4, 2011, p. 129-131.

Research output: Contribution to journalArticle

Shahabi, S, Pellicciotta, I, Hou, J, Graceffa, S, Huang, GS, Samuelson, RN & Goldberg, GL 2011, 'Clinical utility of chromogranin A and octreotide in large cell neuro endocrine carcinoma of the uterine corpus', Rare Tumors, vol. 3, no. 4, pp. 129-131. https://doi.org/10.4081/rt.2011.e41
Shahabi, Shohreh ; Pellicciotta, Ilenia ; Hou, June ; Graceffa, Sarah ; Huang, Gloria S. ; Samuelson, Robert N. ; Goldberg, Gary L. / Clinical utility of chromogranin A and octreotide in large cell neuro endocrine carcinoma of the uterine corpus. In: Rare Tumors. 2011 ; Vol. 3, No. 4. pp. 129-131.
@article{5a865bf4b8694d92b288ab078bb920e6,
title = "Clinical utility of chromogranin A and octreotide in large cell neuro endocrine carcinoma of the uterine corpus",
abstract = "Primary neuroendocrine tumors of the female genital tract have been described in the cervix, ovaries and uterus. Large cell neuroendocrine carcinoma (LCNC) of the uterine corpus is the least common and appears to behave the most aggressively. We report a rare case of a large cell neuroendocrine tumor of the endometrium. These tumors are not well characterized, unlike neuroendocrine tumors of the uterine cervix. Consequently, the optimal management remains still unclear. The treatment of our case consisted of surgery, radiotherapy, chemotherapy, and octreotide. Despite the aggressive treatment, the patient died of disease progression 12 months after the initial diagnosis. We discuss the diagnosis, prognosis, and treatment options for LCNC of the genital tract, and potential future therapeutics.",
keywords = "Chromogranin A, Large cell neuroendocrine carcinoma, Octerotide, Uterine corpus",
author = "Shohreh Shahabi and Ilenia Pellicciotta and June Hou and Sarah Graceffa and Huang, {Gloria S.} and Samuelson, {Robert N.} and Goldberg, {Gary L.}",
year = "2011",
doi = "10.4081/rt.2011.e41",
language = "English (US)",
volume = "3",
pages = "129--131",
journal = "Rare Tumors",
issn = "2036-3605",
publisher = "PagePress",
number = "4",

}

TY - JOUR

T1 - Clinical utility of chromogranin A and octreotide in large cell neuro endocrine carcinoma of the uterine corpus

AU - Shahabi, Shohreh

AU - Pellicciotta, Ilenia

AU - Hou, June

AU - Graceffa, Sarah

AU - Huang, Gloria S.

AU - Samuelson, Robert N.

AU - Goldberg, Gary L.

PY - 2011

Y1 - 2011

N2 - Primary neuroendocrine tumors of the female genital tract have been described in the cervix, ovaries and uterus. Large cell neuroendocrine carcinoma (LCNC) of the uterine corpus is the least common and appears to behave the most aggressively. We report a rare case of a large cell neuroendocrine tumor of the endometrium. These tumors are not well characterized, unlike neuroendocrine tumors of the uterine cervix. Consequently, the optimal management remains still unclear. The treatment of our case consisted of surgery, radiotherapy, chemotherapy, and octreotide. Despite the aggressive treatment, the patient died of disease progression 12 months after the initial diagnosis. We discuss the diagnosis, prognosis, and treatment options for LCNC of the genital tract, and potential future therapeutics.

AB - Primary neuroendocrine tumors of the female genital tract have been described in the cervix, ovaries and uterus. Large cell neuroendocrine carcinoma (LCNC) of the uterine corpus is the least common and appears to behave the most aggressively. We report a rare case of a large cell neuroendocrine tumor of the endometrium. These tumors are not well characterized, unlike neuroendocrine tumors of the uterine cervix. Consequently, the optimal management remains still unclear. The treatment of our case consisted of surgery, radiotherapy, chemotherapy, and octreotide. Despite the aggressive treatment, the patient died of disease progression 12 months after the initial diagnosis. We discuss the diagnosis, prognosis, and treatment options for LCNC of the genital tract, and potential future therapeutics.

KW - Chromogranin A

KW - Large cell neuroendocrine carcinoma

KW - Octerotide

KW - Uterine corpus

UR - http://www.scopus.com/inward/record.url?scp=80355144827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80355144827&partnerID=8YFLogxK

U2 - 10.4081/rt.2011.e41

DO - 10.4081/rt.2011.e41

M3 - Article

C2 - 22355496

AN - SCOPUS:80355144827

VL - 3

SP - 129

EP - 131

JO - Rare Tumors

JF - Rare Tumors

SN - 2036-3605

IS - 4

ER -